CONDENSED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenue:
Genetic testing	$ 483,214	$ 849,422	$ 903,547	$ 1,332,785
Other	45,381	2,706	112,614	6,736
Total revenue	528,595	852,128	1,016,161	1,339,521
Cost of revenue	361,746	496,417	756,517	879,988
Gross profit	166,849	355,711	259,644	459,533
Operating expenses:
Research and development	215,519	187,776	424,696	348,156
Selling, general and administrative	1,506,057	1,573,386	3,032,663	2,575,558
Amortization of intangibles	23,525	25,770	47,050	54,633
Total operating expenses	1,745,101	1,786,932	3,504,409	2,978,347
Loss from operations	(1,578,252)	(1,431,221)	(3,244,765)	(2,518,814)
Other income (expense):
Interest income	1,605	1,401	3,599	2,140
Interest expense	0	(346,491)	0	(461,217)
Total other income (expense)	1,605	(345,090)	3,599	(459,077)
Loss before income taxes	(1,576,647)	(1,776,311)	(3,241,166)	(2,977,891)
Benefit for income taxes	0	0	0	0
Net loss	$ (1,576,647)	$ (1,776,311)	$ (3,241,166)	$ (2,977,891)
Basic and diluted net loss per common share	$ (0.01)	$ (0.02)	$ (0.03)	$ (0.05)
Weighted average common shares outstanding, basic and diluted	122,516,317	79,006,278	122,499,091	58,007,551